Total Debt to Capital: Cyclacel (CYCC)

Cyclacel Pharmaceuticals (CYCC) develops cell cycle regulation agents for the therapy of solid tumors in the UK and the US. This market valuation chart reflects a debt load of 0.00, which is critical amid cost optimization and anticipation of trial data for the fadraciclib inhibitor. The business operations are protected by the humanitarian status of biomedicine, minimizing the impact of external political shocks.

cyclacel.com (CYCC): Debt to Equity Ratio from 07/04/2022 to 09/12/2025

Cyclacel, Inc. - analytical breakdowns and key metrics (CYCC)

- share price and consensus valuation forecast:

Stock Price Cyclacel|CYCC - Analyst Target Range

- company stock exchange capitalization indicators:

Market Capitalization Cyclacel|CYCC - Total Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Cyclacel|CYCC - Accounting Capitalization|Market Capitalization to Book Value Ratio cyclacel.com|CYCC - Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

CYCC - Company Net Income

Basic company analysis:CYCC, Cyclacel

This metric measures the business's degree of dependence on borrowed funds by comparing total liabilities to equity to assess financial stability. By analyzing the total debt-to-equity ratio, an investor can evaluate the extent to which the capital-intensive cancer drug development and patent portfolio of Cyclacel Pharmaceuticals (CYCC) rely on leverage or internal resources.

Key competitors